Stop Press:

Chromadex the dietary supplement supplier reports on human trials just completed and a further 2 reports with FDA.

 

 

https://www.jci.org/articles/view/138538   & https://investors.chromadex.com/news/news-details/2020/New-Pilot-Study-Indicates-Niagen-May-Reduce-Inflammatory-Cytokines-in-Stage-D-Heart-Failure-Patients/default.aspx

China’s nicotinamide mononucleotide (NMN) supplier EffePharm announced in February was embarking on its first human clinical trial as it seeks to validate the anti-ageing effects and safety of its ingredient “Uthever”.

A product we use.

http://www.effepharm.com/en/xwzx/info.aspx?itemid=159&lcid=19